It might take a while longer, but Pfizer is on the path to recovery. Is 2026 the year Pfizer (NYSE: PFE) finally turns things ...

Pfizer Inc. (NYSE:PFE) ranks among the best stocks under $25 to buy now. Citing the company’s cautious 2026 outlook, BMO ...

More than a dozen pharmas have recently struck deals with the White House to lower drug prices. Nevertheless, drugmakers ...

In the latest close session, Pfizer (PFE) was up +1.12% at $25.18. The stock outpaced the S&P 500's daily gain of 0.19%. Meanwhile, the Dow experienced a rise of 0.66%, and the technology-dominated ...

Pfizer enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution. Click here to read ...

Let’s dive into details regarding each of the evaluated factors, but first, for quick context: With $143 Bil in market ...

Drugmakers hike prices 350 drugs in January, including Pfizer's COVID-19 vaccine and hospital drugs, with a median increase of 4%.

Pfizer enters the new year as a company in transition, but one with a heavily fortified bottom line. Management has set a revenue floor of approximately $61 billion for 2026. This is a realistic, ...

A patient in an open label extension study of Pfizer’s hemophilia treatment Hympavzi has died, the company and several ...

A patient who was being treated with Pfizer's hemophilia drug, Hympavzi, as part of a long-term study died after experiencing ...

By the beginning of 2025, it was clear the GLP-1 drugs were going to remain a major part of the industry. Pfizer used its presentation at the 43 rd JP Morgan Healthcre Conference to detail plans to ...

A patient died after receiving Pfizer Inc.’s drug for hemophilia, marking another setback for the company in the treatment of ...